1. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. (4th May 2018) Authors: Mooradian, Meghan J.; Reuben, Alexandre; Prieto, Peter A.; Hazar-Rethinam, Mehlika; Frederick, Dennie T.; Nadres, Brandon; Piris, Adriano; Juneja, Vikram; Cooper, Zachary A.; Sharpe, Arlene H.; Corcoran, Ryan B.; Flaherty, Keith T.; Lawrence, Donald P.; Wargo, Jennifer A.; Sullivan, Ryan J. Journal: Oncoimmunology Issue: Volume 7:Number 5(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗